Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) Director Sangeeta Bhatia sold 271 shares of Vertex Pharmaceuticals stock in a transaction on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the completion of the sale, the director directly owned 4,653 shares in the company, valued at $2,549,192.58. This represents a 5.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ VRTX opened at $514.75 on Friday. The firm has a market cap of $130.51 billion, a PE ratio of 31.62, a PEG ratio of 2.85 and a beta of 0.28. The firm has a fifty day moving average of $522.72 and a 200 day moving average of $485.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34. Vertex Pharmaceuticals Incorporated has a one year low of $412.27 and a one year high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the business earned $4.80 earnings per share. The business’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Institutional Investors Weigh In On Vertex Pharmaceuticals
A number of large investors have recently modified their holdings of VRTX. BlackRock Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter worth $11,975,849,000. Bank of America Corp DE purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $1,509,651,000. Legal & General Group Plc acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth $928,893,000. Bank of New York Mellon Corp acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth $830,842,000. Finally, Deutsche Bank AG purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $784,391,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.
Analysts Set New Price Targets
VRTX has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, November 9th. Wells Fargo & Company lifted their price objective on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. TD Cowen increased their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Finally, Daiwa Securities Group raised their target price on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.
View Our Latest Analysis on VRTX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
